Arbutus Biopharma Co. (NASDAQ:ABUS) Position Increased by Woodline Partners LP

Woodline Partners LP increased its position in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 45.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 971,628 shares of the biopharmaceutical company's stock after purchasing an additional 303,475 shares during the quarter. Woodline Partners LP owned 0.51% of Arbutus Biopharma worth $3,177,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Rangeley Capital LLC purchased a new position in Arbutus Biopharma in the 4th quarter valued at about $4,771,000. JPMorgan Chase & Co. lifted its stake in Arbutus Biopharma by 900.4% during the fourth quarter. JPMorgan Chase & Co. now owns 896,258 shares of the biopharmaceutical company's stock worth $2,931,000 after purchasing an additional 806,672 shares during the last quarter. Two Seas Capital LP boosted its holdings in shares of Arbutus Biopharma by 4.2% in the 4th quarter. Two Seas Capital LP now owns 8,740,956 shares of the biopharmaceutical company's stock valued at $28,583,000 after buying an additional 353,568 shares during the period. BlackBarn Capital Partners LP boosted its stake in Arbutus Biopharma by 13.1% in the fourth quarter. BlackBarn Capital Partners LP now owns 2,341,871 shares of the biopharmaceutical company's stock valued at $7,658,000 after acquiring an additional 270,971 shares during the period. Finally, Saba Capital Management L.P. grew its stake in Arbutus Biopharma by 31.3% during the 4th quarter. Saba Capital Management L.P. now owns 887,993 shares of the biopharmaceutical company's stock worth $2,904,000 after buying an additional 211,566 shares during the last quarter. 43.79% of the stock is owned by institutional investors and hedge funds.

Arbutus Biopharma Stock Performance

NASDAQ ABUS traded down $0.06 on Friday, reaching $3.39. The company's stock had a trading volume of 91,397 shares, compared to its average volume of 991,423. Arbutus Biopharma Co. has a twelve month low of $2.71 and a twelve month high of $4.73. The firm's 50 day moving average is $3.27 and its two-hundred day moving average is $3.34. The stock has a market cap of $648.32 million, a PE ratio of -7.90 and a beta of 1.50.

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.04). Arbutus Biopharma had a negative net margin of 1,137.65% and a negative return on equity of 68.18%. The business had revenue of $1.76 million for the quarter, compared to the consensus estimate of $2.54 million. Equities research analysts anticipate that Arbutus Biopharma Co. will post -0.39 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Chardan Capital restated a "buy" rating and issued a $5.00 target price on shares of Arbutus Biopharma in a research report on Friday, March 28th. Wall Street Zen upgraded Arbutus Biopharma from a "sell" rating to a "hold" rating in a research report on Saturday, March 29th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $5.50.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.